-
May 21, 2013
After a month of speculation, Actavis has announced it is buying Warner Chilcott in a stock-for-stock agreement worth $8.5 billion
Full story
-
May 11, 2013
Actavis and Warner Chilcott have announced that they are engaged in preliminary discussions regarding a possible merger
Full story
-
February 25, 2013
Warner Chilcott says that its fourth-quarter net income leapt 37.8%, though pharmaceutical sales were hurt by the impact of generic competition for its osteoporosis drug Actonel
Full story
-
November 12, 2012
Warner Chilcott says that its third-quarter earnings have tripled, though pharmaceutical sales fell due to impact of generic competition for its osteoporosis drug Actonel
Full story
-
August 20, 2012
German drugmaker Bayer AG has filed a complaint against US group Warner Chilcott claiming infringement of patents with the sale of its contraceptive Lo Loestrin.
Full story
-
May 01, 2012
As rumours about a takeover bid from Bayer gather pace, Warner Chilcott has announced that it is looking at its future options which include a sale
Full story
-
February 27, 2012
Ireland-based drugmaker Warner Chilcott has posted a reasonable set of financials despite suffering the impact of generic competition for its osteoporosis drug Actonel
Full story
-
September 30, 2010
Warner Chilcott UK has decided to withdraw its application to extend the treatment scope of its female sexual dysfunction patch Intrinsa (testosterone) in Europe, due to “commercial considerations”.
Full story
-
September 27, 2010
Novartis is selling the US rights to the overactive bladder treatment Enablex to Warner Chilcott in a deal worth around $420 million to the Swiss major
Full story